Overall, Alterations in the expression of VCL, FLNA, TAGLN, ACTA2, COL6A2, and CALD1 may play important roles in the development of bladder cancer, suggesting their potential value in early detection, molecular subtyping, and targeted therapy. This evidence concerns the gene ACTA2 and urinary bladder cancer.